| 王悦,李京,范慧红.首批依诺肝素钠国家对照品1,6-脱水衍生物含量赋值的协作研究[J].中国药事,2022,36(7):772-779 |
| 首批依诺肝素钠国家对照品1,6-脱水衍生物含量赋值的协作研究 |
| The Collaborative Study on the Content Assignment of 1,6-anhydro Derivatives of the 1st Enoxaparin National Standard |
| |
| DOI：10.16153/j.1002-7777.2022.07.005 |
| 中文关键词: 依诺肝素钠 1 6-脱水衍生物 对照品 国家标准 协作标定 |
| 英文关键词: enoxaparin sodium 1 6-anhydro derivatives standard Chinese national standard collaborative study |
| 基金项目:国家重大新药创制课题(编号 2015ZX09303001)；学科带头人培养基金课题(编号 2021X6) |
|
| 摘要点击次数: 884 |
| 全文下载次数: 316 |
| 中文摘要: |
| 目的： 建立首批1,6-脱水衍生物系统适用性对照品，完善国家标准。方法：以欧洲药典依诺肝素钠对照品(EP Enoxaparin Sodium，Batch5)为系统适用性对照品，采用依诺肝素钠新国家标准草案 “1,6-脱水衍生物”检查法，对依诺肝素钠国家对照品(批号：140810-201801)进行1,6-脱水衍生物含量测定，由全国14个药品检验机构及依诺肝素生产企业实验室协作标定。结果：对依诺肝素钠系统适用性国家对照品(批号：140810-201801)1,6-脱水衍生物含量标定结果为20.3%，并对实验室内误差进行考察，14个实验室中有1个实验室(Lab1)标准差(SD)为1.8%，5个实验室(Lab2、Lab4、Lab10、 Lab11和Lab13)的SD为0.5%~0.7%，其余8个实验室的SD值均小于0.5%。对实验室间误差进行考察，有效数据的SD值为0.6%，相对标准偏差(RSD)为3.2%。结论：经国家药品标准物质委员会审定后批准， 依诺肝素系统适用性国家对照品(批号：140810-201801)增加1,6-脱水衍生物含量赋值，可以用于依诺肝素钠1,6-脱水衍生物检查系统适用性考察使用。 |
| 英文摘要: |
| Objective: The new draft of National standard for enoxaparin sodium has added the determination item of 1,6-anhydro derivatives. The 1st batch of 1,6-anhydro derivatives of national reference standard should be established for systematic applicability. Methods: The European Pharmacopoeia enoxaparin sodium reference substance (EP enoxaparin sodium, batch 5) was used as the system applicability reference substance. The national standard (batch number: 140810-201801) of enoxaparin was used to determine the content of 1,6-anhydro derivatives by the new national standard draft "1, 6-dehydrated derivatives" examination method, which was determined by 14 national drug inspection institutions and laboratories of enoxaparin manufacturers. Results: The content calibration result of 1,6-anhydroderivatives was 20.3% in the national standard (batch number: 140810-201801) applicable to enoxaparin sodium system, and the laboratory errors were investigated. Among the 14 laboratories, the standard deviation (SD) of 1 laboratory (Lab1) was 1.8%, the SD of 5 laboratories (Lab2, Lab4, Lab10, Lab11 and Lab13) was 0.5%-0.7%, and the SD values of the remaining 8 laboratories were all less than 0.50%. When the interlaboratory errors were examined, the SD of the valid data was 0.6%, and the relative standard deviation (RSD) was 3.2%. Conclusion: After approval by National Drug Standard Substances Committee, the national standard applicable to enoxaparin sodium (batch number: 140810-201801) was approved to add the content assignment value of 1,6-anhydro derivatives. This national standard could be used in the test of enoxaparin 1,6-dehydrated derivatives in enoxaparin sodium Chinese national standard. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|